In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over ...

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...

ABSTRACT: Microfluidic wearables move microliter biofluids across soft, low-impedance interfaces and into stable transducers on skin, enabling time-stamped chemistry without pumps. In this review ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...

The CGM provides real-time glucose readings for 15.5 days. “As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” ...

ARLINGTON, VA / ACCESS Newswire / August 13, 2025 / FriskaAi announced today an agreement with DexCom, Inc., the global leader in glucose biosensing, to integrate data from Dexcom G7 and Dexcom G6 ...

NEW YORK CITY, NY / ACCESS Newswire / November 15, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DXCM) and certain ...

Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in a new awareness campaign. The project kicked off Friday, World Diabetes Day ...

Dexcom has issued a Class I recall for its G6 glucose sensor Android application due to a defect that causes the app to crash unexpectedly. As a result of the app terminating, users could miss ...

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...